Six patients with Kawasaki disease (KD) were treated with prednisolone (1 to 2 mg/kg/day) for 3 days (from days 10 to 12 after the onset of the illness) after apparently unsuccessful treatment with intravenous immunoglobulin (IVIG, 2 g/kg/dose and additional 1 g/kg/dose). Five patients responded immediately to the first course of prednisolone infusion. One patient failed to respond to the first course of prednisolone therapy, but he did respond to the second 3-day course of therapy. None of the patients demonstrated a further progression of coronary artery dilatation or any adverse effects. Standard-dose and short-term corticosteroid therapy therefore appears to be a safe and effective treatment for patients with IVIG-resistant KD.
Get full access to this article
View all access options for this article.
References
1.
Newburger JW, Takahashi M, Burns JC, et al.The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986;315:341-347.
2.
Newburger JW, Takahashi M, Beiser AS, et al.A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med. 1991;324:1633-1639.
3.
Hashino K, Ishii M, Iemura M, et al.Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int. 2001;43:211-217.
4.
Wright DA, Newburger JW, Baker A, Sundel RP. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr. 1996;128:146-149.
5.
Raman V, Kim J, Sharkey A, Chatila T. Response of refractory Kawasaki disease to pulse steroid and cyclosporin A therapy. Pediatr Infect Dis J. 2001;20:635-637.
6.
Suzuki N, Seguchi M, Kouno C, et al.Rupture of coronary aneurysm in Kawasaki disease. Pediatr Int. 1999;4:318-320.
7.
Takahashi K, Oharaseki T, Wakayama M, et al.Pathological study of ruptured coronary artery aneurysms of Kawasaki disease (KD). Abstract from the 2nd World Congress of Pediatric Cardiology and Cardiac Surgery. 11-17 May 1997; p202.
8.
Baethge BA, Lidsky MD, Goldberg JW. A study of adverse effects of high-dose intravenous (pulse) methylprednisolone therapy in patients with rheumatic disease. Ann Pharmacother. 1992;26:316-320.
9.
Dale RC, Saleem MA, Daw S, Dillon MJ. Treatment of severe complicated Kawasaki disease with oral prednisolone and aspirin. J Pediatr. 2000;137:723-726.
10.
Takagi N, Kihara M, Yamaguchi S, et al.Plasma exchange in Kawasaki disease. Lancet. 1995;346:1307.
11.
Imagawa T, Miyamae T, Ito S, et al.Plasma exchange for intractable Kawasaki disease. Presented at 6th International Kawasaki Disease Symposium; 1999; Hawaii, USA.
12.
Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics. 1979;63:175-179.
Shinohara M, Sone K, Tomomasa T, Morikawa A. Corticosteroids in the treatment of the acute phase of Kawasaki disease. J Pediatr. 1999;135:465-469.
15.
Schwiebert LM, Beck LA, Stellato C, et al.Glucocorticosteroid inhibition of cytokine production: relevance to antiallergic actions. J Allergy Clin Immunol. 1996;97(1 Pt 2):143-152.
16.
Leung DY, Cotran RS, Kurt-Jones E, et al.Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease. Lancet. 1989;2:1298-1302.
17.
Suzuki A, Miyagawa-Tomita S, Komatsu K, et al.Active remodeling of the coronary arterial lesions in the late phase of Kawasaki disease: immunohistochemical study. Circulation. 2000;101:2935-2941.
18.
Nakano M. Evaluation of new urinastatin therapy for the acute phase of Kawasaki disease. Abstract from the 7th International Kawasaki disease synposium. 4-7, December 2001; P50.
19.
Zaitsu M, Hamasaki Y, Tashiro K, et al.Ulinastatin, an elastase inhibitor, inhibits the increased mRNA expression of prostaglandin H2 synthase-type 2 in Kawasaki disease. J Infect Dis. 2000;181:1101-1109.
